Thorne Research Introduces a New Product, NiaCel(TM), Featuring NIAGEN(TM), To Support Healthy Aging
IRVINE, Calif., April 2, 2014 /PRNewswire/ — Thorne Research today announced the launch of NiaCel(TM), an innovative nutritional supplement that supports endurance, energy, and healthy aging. NiaCel(TM) is one of the first commercially available products to feature the ingredient NIAGEN(TM) from ChromaDex Corp.( )(OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic, and pharmaceutical industries.
ChromaDex developed its breakthrough patent-protected ingredient NIAGEN(TM) as the first and only commercially available brand of nicotinamide riboside (NR). NR, the active ingredient in NiaCel(TM), boosts levels of NAD+ in cells and tissue. Studies have demonstrated that increasing the levels of NAD+ can support healthy aging by stimulating mitochondrial energy production, as well as by activating sirtuin function.
Paul Jacobson, the CEO of Thorne Research, stated, “We are very excited to offer NIAGEN nicotinamide riboside to our practitioner network through this new, exclusive product launch. NiaCel provides practitioners with a powerful new solution to promote healthy aging in patients. NIAGEN is one of the most innovative new ingredients developed in the past decade. We are thrilled to partner together with ChromaDex and our practitioner-customer base to enhance patient health with the introduction of NiaCel.”
Frank Jaksch, ChromaDex founder and CEO, stated, “NiaCel is truly a groundbreaking product. We are pleased to have Thorne Research feature NIAGEN, our branded nicotinamide riboside, in such a prominent product launch.”
About Nicotinamide Riboside (NR):
Sometimes referred to as the “Miracle Molecule” or “Hidden Vitamin,” NR is found naturally in trace amounts in milk and other foods and is a more potent, no-flush vitamin B3 (Niacin) derivative.
Published research has shown that NR is perhaps the most effective NAD+ booster, an essential metabolite found in all cells. NAD+ is arguably the most important cellular co-factor for improvement of mitochondrial performance and energy metabolism. Mitochondria are the powerhouse of the cell where macronutrients are converted to energy the cell can use. Mitochondria also play an important part in the aging process. It is hoped that by stimulating mitochondrial function with the NR molecule scientists will see increased longevity as well as other health improvements. Researchers worldwide continue seminal discoveries characterizing the unique properties of NR in a wide range of health benefits. These include increasing mitochondrial health, increasing muscle endurance, neuroprotection, sirtuin activation, protection against weight gain on a high-fat diet, protection against oxidative stress, improvement of blood glucose, and insulin sensitivity to maintain blood sugar levels within the normal range.
Findings from a recent study by Weill Cornell Medical College and the Ecole Polytechnique Federale de Lausanne, Switzerland researchers showed that mice on a high-fat diet that were fed NR gained 60-percent less weight than mice eating the same high-fat diet without NR. Moreover, unlike the mice that were not fed NR, none of the NR-treated mice had indications they were developing diabetes and they had improved energy and lower cholesterol levels, all without side effects. The Swiss researchers were quoted as saying the effects of NR on metabolism “are nothing short of astonishing.”
A study by researchers from Harvard Medical School in conjunction with the National Institute on Aging, published in December 2013 in CELL, demonstrated that mitochondrial dysfunction (a hallmark of aging) in aging mice is due to a disruption in sirtuin1-dependent nuclear-mitochondrial communication. They further showed that a reduction in NAD+ levels is responsible for this disruption. They also showed this mitochondrial dysfunction was readily reversible by administration of a NAD+ precursor. The authors found that “one week of treatment with a compound that boosts NAD+ levels is sufficient to restore the mitochondrial homeostasis and key biochemical markers of muscle health in a 22-month-old mouse to levels similar to a 6-month-old mouse.”
About ChromaDex Corp.:
ChromaDex is an innovative natural products company that discovers, acquires, develops, and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as “phytochemicals”), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic, and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure(®) pterostilbene; ProC3G(®), a natural black rice containing cyanidin-3-glucoside; PURENERGY(TM), a caffeine-pTeroPure(®) co-crystal; and NIAGEN(TM), its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com.
About Thorne Research, Inc.:
Since 1984, Thorne Research, with more than 400 nutritional supplement products, has set the standard for exceptional quality manufacturing and formulation of pure, highly absorbable nutritional supplements using advanced technology. Thorne Research is recognized as a global leader and provider of nutritional supplements and education to licensed health-care practitioners. With locations in Sandpoint, Idaho, and New York City, Thorne Research operates a state-of-the-art manufacturing facility and employs more than 260 people. Further information on Thorne Research is available at www.thorne.com.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects”, “anticipates”, “intends”, “estimates”, “plans”, “potential”, “possible”, “probable”, “believes”, “seeks”, “may”, “will”, “should”, “could” or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended December 28, 2013, the Company’s Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
ChromaDex Company Contact:
Laura Carney, Executive Assistant
Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.
SOURCE ChromaDex Corp.